Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Secondary surgery extends OS in recurrent ovarian cancer

Publish date:: June 3, 2020

Key clinical point: Secondary cytoreductive surgery can improve overall survival in some patients with recurrent ovarian cancer.

Major finding: The median overall survival was 53.7 months with surgery plus chemotherapy and 46 months with chemotherapy alone (P = .02).

Study details: A randomized, phase 3 trial of 407 women with recurrent ovarian cancer who were platinum free for more than 6 months.

Disclosures: The study was sponsored by the AGO study group in collaboration with other oncology groups, Medac, and GlaxoSmithKline. Dr. du Bois disclosed relationships with several companies.

Citation:

du Bois A et al. ASCO 2020, Abstract 6000.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,